Patents by Inventor Joon-Yong Chung
Joon-Yong Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240069028Abstract: Provided are biomarkers for predicting the prognosis of cervical cancer. In the case of using the biomarkers of the present disclosure, it is possible to select patients into a high-risk group, an intermediate-risk group, or a low-risk group, and thus, it is possible to provide tailored treatment for each patient according to prognosis prediction.Type: ApplicationFiled: August 23, 2023Publication date: February 29, 2024Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Hanbyoul Cho, Jae-Hoon Kim, Joon-Yong Chung, Hee Yun, Gwan Hee Han, Hye Rim Kim
-
Publication number: 20220291094Abstract: Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.Type: ApplicationFiled: April 8, 2022Publication date: September 15, 2022Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Stephen M. Hewitt, Joon-Yong Chung, Candice D. Perry, Robert A. Star
-
Patent number: 11313772Abstract: Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.Type: GrantFiled: November 11, 2016Date of Patent: April 26, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen M. Hewitt, Joon-Yong Chung, Candice D. Perry, Robert A. Star
-
Patent number: 11237169Abstract: Compositions, methods and kits are described for identifying biomolecules (e.g., proteins and nucleic acids) expressed in a biological sample that are associated with the presence, development, or progression of a disease (such as cancer), or more generally determination of the etiology or risk factors associated with a disease. Sample types analyzed by the disclosed methods include but are not limited to archival tissue blocks that have been preserved in a fixative, tissue biopsy samples, tissue microarrays, and so forth. The methods disclosed herein correlate expression profiles of biomolecules with various disease types, and allow for the determination of relative survival rates; in some embodiments, the methods permit determination of survival rates for a subject with cancer. In other embodiments, the disclosure relates to methods for evaluating therapeutic regimes for the treatment, such as treatment of cancer.Type: GrantFiled: December 12, 2018Date of Patent: February 1, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen M. Hewitt, Joon-Yong Chung
-
Publication number: 20200041389Abstract: Disclosed herein are compositions for fixing tissue for cytologic, histomorphologic, and/or molecular analysis (e.g., DNA, RNA, and/or protein analysis). In some embodiments, the fixatives are aldehyde-free fixatives, for example, formaldehyde- or formalin-free fixatives. Particular disclosed compositions include buffered ethanol. The buffer is a phosphate buffer or phosphate buffered saline (PBS) in some examples. In further embodiments, the fixative includes additional components, such as glycerol and/or acetic acid.Type: ApplicationFiled: November 11, 2016Publication date: February 6, 2020Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Stephen M. Hewitt, Joon-Yong Chung, Candice D. Perry, Robert A. Star
-
Publication number: 20190113517Abstract: Compositions, methods and kits are described for identifying biomolecules (e.g., proteins and nucleic acids) expressed in a biological sample that are associated with the presence, development, or progression of a disease (such as cancer), or more generally determination of the etiology or risk factors associated with a disease. Sample types analyzed by the disclosed methods include but are not limited to archival tissue blocks that have been preserved in a fixative, tissue biopsy samples, tissue microarrays, and so forth. The methods disclosed herein correlate expression profiles of biomolecules with various disease types, and allow for the determination of relative survival rates; in some embodiments, the methods permit determination of survival rates for a subject with cancer. In other embodiments, the disclosure relates to methods for evaluating therapeutic regimes for the treatment, such as treatment of cancer.Type: ApplicationFiled: December 12, 2018Publication date: April 18, 2019Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Stephen M. Hewitt, Joon-Yong Chung
-
Publication number: 20180074076Abstract: Compositions, methods and kits are described for identifying biomolecules (e.g., proteins and nucleic acids) expressed in a biological sample that are associated with the presence, development, or progression of a disease (such as cancer), or more generally determination of the etiology or risk factors associated with a disease. Sample types analyzed by the disclosed methods include but are not limited to archival tissue blocks that have been preserved in a fixative, tissue biopsy samples, tissue microarrays, and so forth. The methods disclosed herein correlate expression profiles of biomolecules with various disease types, and allow for the determination of relative survival rates; in some embodiments, the methods permit determination of survival rates for a subject with cancer. In other embodiments, the disclosure relates to methods for evaluating therapeutic regimes for the treatment, such as treatment of cancer.Type: ApplicationFiled: August 14, 2017Publication date: March 15, 2018Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Stephen M. Hewitt, Joon-Yong Chung, Udayan Guha
-
Patent number: 9714409Abstract: The invention may be broadly defined as the addition of Argon to FFPE procedures as an RNA stabilizing agent. Argon is an inert gas from the Noble gas group with low saturation concentrations in water. It is therefore highly surprising that Argon would have any effect on RNA stability in the presence of Formalin, or any other chemical. This property of Argon appears to be specific in that other inert gases fail to show any RNA stabilizing effect.Type: GrantFiled: August 16, 2013Date of Patent: July 25, 2017Assignees: American Air Liquide, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Vasuhi Rasanayagam, Sagar D. Joshi, Meenakshi Sundaram, Stephen M. Hewitt, Joon-Yong Chung
-
Publication number: 20170168059Abstract: A method for selecting treatment options for patients is provided. The method comprises a procedure for selecting patients that should not be placed on Active Surveillance (AS) but receive active treatment even though the morphologic analysis of the patient's biopsy may show a Gleason score that would traditionally have placed the patient in AS without any further treatment. In accordance with one embodiment, the patient is selected for active treatment if a biomarker associated with prostate cancer is detected. In yet a further embodiment, the patient is selected for additional treatment if the biomarker's concentration is determined to be higher in the benign section of the tissue sample than in the cancerous section. In another embodiment, biochemical recurrence is predicted identifying patients for treatment.Type: ApplicationFiled: February 9, 2015Publication date: June 15, 2017Inventors: Robert W. VELTRI, Hui ZHANG, Christhunesa CHRISTUDASS, Zhi LIU, Jonathan I. EPSTEIN, H. Ballantine CARTER, Guangjing ZHU, Christine DAVIS, Stephen M. HEWITT, Joon-Yong CHUNG
-
Publication number: 20170115295Abstract: Compositions, methods and kits are described for identifying biomolecules (e.g., proteins and nucleic acids) expressed in a biological sample that are associated with the presence, development, or progression of a disease (such as cancer), or more generally determination of the etiology or risk factors associated with a disease. Sample types analyzed by the disclosed methods include but are not limited to archival tissue blocks that have been preserved in a fixative, tissue biopsy samples, tissue microarrays, and so forth. The methods disclosed herein correlate expression profiles of biomolecules with various disease types, and allow for the determination of relative survival rates; in some embodiments, the methods permit determination of survival rates for a subject with cancer. In other embodiments, the disclosure relates to methods for evaluating therapeutic regimes for the treatment, such as treatment of cancer.Type: ApplicationFiled: November 11, 2016Publication date: April 27, 2017Applicant: The United States of America, as represented by the Secretary, Dept of Health and Human ServicesInventors: Stephen M. Hewitt, Joon-Yong Chung
-
Publication number: 20150216161Abstract: The invention may be broadly defined as the addition of Argon to FFPE procedures as an RNA stabilizing agent. Argon is an inert gas from the Noble gas group with low saturation concentrations in water. It is therefore highly surprising that Argon would have any effect on RNA stability in the presence of Formalin, or any other chemical. This property of Argon appears to be specific in that other inert gases fail to show any RNA stabilizing effect.Type: ApplicationFiled: August 16, 2013Publication date: August 6, 2015Applicant: American Air Liquide, Inc.Inventors: Vasuhi Rasanayagam, Sagar D. Joshi, Meenakshi Sundaram, Stephen M. Hewitt, Joon-Yong Chung
-
Publication number: 20110306514Abstract: Compositions, methods and kits are described for identifying biomolecules (e.g., proteins and nucleic acids) expressed in a biological sample that are associated with the presence, development, or progression of a disease (such as cancer), or more generally determination of the etiology or risk factors associated with a disease. Sample types analyzed by the disclosed methods include but are not limited to archival tissue blocks that have been preserved in a fixative, tissue biopsy samples, tissue microarrays, and so forth. The methods disclosed herein correlate expression profiles of biomolecules with various disease types, and allow for the determination of relative survival rates; in some embodiments, the methods permit determination of survival rates for a subject with cancer. In other embodiments, the disclosure relates to methods for evaluating therapeutic regimes for the treatment, such as treatment of cancer.Type: ApplicationFiled: January 13, 2010Publication date: December 15, 2011Applicant: UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Stephen M. Hewitt, Joon-Yong Chung